ClinChoice Widens Global Footprint By Acquiring CSI Medical Research

ClinChoice, a leading worldwide Contract Research Organization (CRO), has expanded its global reach with the purchase of CSI Medical Research.

CSI is a regional clinical CRO with professional staff and partners located across Southeast Asia (SEA), Australia and New Zealand (ANZ), to provide innovative and cost-effective clinical solutions. Through this strategic acquisition, ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around the world, as per pharmabiz.

In recent years, the overall atmosphere and infrastructure supporting clinical research in Southeast Asia have improved dramatically. With a huge population, an expanding economy, and mature regulatory processes and healthcare systems, the SEA has attracted an increasing number of biotech and pharmaceutical businesses to perform clinical research and drug development trials in the region.

CSI, founded in 2017, has quickly emerged as a leading regional CRO with a track record of successfully completing clinical studies in Southeast Asia. CSI's management team is made up of experienced clinical research specialists who previously worked for some of the industry's most well-known companies. The Company has managed a wide range of clinical trials because to its comprehensive knowledge of local practice, standards, and legislation.

ClinChoice, a worldwide CRO, is committed to offering full-service and functional solutions across the development lifecycle to pharmaceutical, biotechnology, medical device, and consumer product firms both locally and abroad. ClinChoice has over 4,000 people worldwide, providing comprehensive regulatory expertise, clinical trial execution, and data management capabilities in all major markets and regions.   ClinChoice has completed over 1,500 full-service clinical studies throughout all clinical trial phases and in all key therapeutic areas since its inception in 1995.